# Gastric Cancer Aspirin is biologically relevant in **gastric cancer** for a simple reason. This cancer often grows out of long-standing inflammation. That is especially true when ***Helicobacter pylori*** is part of the story. Aspirin intersects with that biology at several levels. It affects **COX-2**, inflammatory signalling, platelet-driven metastasis, and the **TXA2** pathway. Those are all relevant in gastric disease. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) The evidence is still mostly **observational**. There is no **Phase 3 adjuvant gastric-cancer trial** yet. That means the signal is encouraging, but not definitive. ### Overview Unlike colorectal cancer, gastric cancer does not yet have a biomarker-selected aspirin trial that settles the question. What it does have is a strong mechanistic rationale plus repeated observational findings. The most important modifier is ***H. pylori***** infection**. Across several populations, aspirin's apparent protective effect is strongest in people with current or prior ***H. pylori*** exposure. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10022803/) That matters because gastric cancer is not one biology. The aspirin signal looks stronger in **non-cardia** disease than **cardia** disease. It also looks stronger in **intestinal-type** disease than **diffuse-type** disease. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) {% hint style="warning" %} The key caution is also simple. People with gastric cancer often already have vulnerable gastric lining, prior ulcer history, or altered anatomy after surgery. That makes aspirin decisions more individual here than in many other cancer settings. {% endhint %} ### Key human data #### Population and case-control signal The 2025 high-incidence population study is one of the most striking recent results. In a population with very high **CagA-positive *****H. pylori*** burden, regular aspirin use was linked to a **51% lower gastric-cancer risk** after adjustment for confounders, with an adjusted odds ratio of **0.49**. Non-aspirin NSAIDs did not show the same protection. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/40478405/) That matters because it suggests the signal may be more specific to aspirin than to NSAIDs as a class. #### The H. pylori interaction Several earlier studies point in the same direction. In a Russian case-control study, the odds ratio for gastric cancer was **0.39** in ***H. pylori*****–infected** aspirin users, while the association was much weaker or absent in uninfected people. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) A Swedish case-control study showed a similar pattern, with an odds ratio of **0.60** in ***H. pylori*****–positive** aspirin users versus **0.80** in uninfected users. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) A Taiwan nationwide retrospective study also supported this interaction. Gastric-cancer risk fell by about **50%** in ***H. pylori*****–infected** aspirin users, compared with a smaller reduction in uninfected users. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) Taken together, that makes the infection link hard to dismiss. #### Subtype matters Meta-analyses and pooled observational work suggest aspirin is more protective in **non-cardia gastric cancer** than in **cardia cancer**. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) That fits the biology. **Non-cardia** disease is more tightly linked to ***H. pylori***, chronic mucosal inflammation, and **COX-2** activation. The same pattern appears by histology. The protective signal is usually stronger in **intestinal-type** gastric cancer than in **diffuse-type** disease. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) #### Cohort and infection-related context The **NHS/NHSII** analysis also found that regular aspirin use was associated with lower ***H. pylori*** infection risk in women. [Read the cohort paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC10022803/) That does not prove aspirin eradicates infection in real patients. It does support the idea that aspirin may influence both the inflammatory driver and the downstream cancer risk. ### The H. pylori connection ***H. pylori*** is the biggest known gastric-cancer driver worldwide. It is thought to account for roughly **three quarters** of gastric-cancer cases globally. [Read the AACR review](https://aacrjournals.org/cancerpreventionresearch/article/15/4/213/682290/Role-of-Aspirin-in-Gastric-Cancer) The carcinogenic path is well described: * ***H. pylori*** drives chronic mucosal inflammation * that raises **COX-2** expression * **COX-2** increases **prostaglandin E2** * that promotes proliferation, reduces apoptosis, and supports tumour development There is also a second layer. ***H. pylori*** can drive **hypergastrinemia**, which in turn upregulates **COX-2** transcription through **PI3K-related** signalling. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10022803/) That means the aspirin-sensitive axis is not just inflammation in the abstract. It is connected directly to a well-known gastric-cancer driver. Some in vitro work also suggests aspirin can inhibit ***H. pylori*** growth in a dose-dependent way. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10022803/) That is not the same as saying aspirin is an anti-*H. pylori* treatment. It does strengthen the biological plausibility. > The most interesting gastric-cancer aspirin story is not a single pathway. > > It is the overlap between infection, inflammation, **COX-2**, **PI3K**, and metastasis biology. ### Mechanistic relevance #### COX-2 and PGE2 This is the most established gastric-cancer aspirin mechanism. **COX-2** is frequently overexpressed in gastric tumours, especially in ***H. pylori*****–associated**, **intestinal-type**, **non-cardia** disease. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) A 2024 gastrointestinal-cancers review reported that **81 mg/day aspirin** inhibits the **COX–PGE2** mechanism by about **45%**, while higher-dose ibuprofen is needed to reach stronger inhibition. [Read the review](https://www.tandfonline.com/doi/full/10.1080/29937817.2024.2411460) That helps explain why even low-dose aspirin remains mechanistically relevant in gastric-cancer discussions. #### PIK3CA and PI3K pathway biology **PIK3CA** mutations occur in a minority of gastric cancers, roughly **10% to 15%** in many series. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9250486/) But the gastric story may be wider than mutation alone. Because ***H. pylori*** and hypergastrinemia can push **PI3K** signalling upstream, some gastric tumours may have aspirin-relevant **PI3K pathway pressure** even without a classic **PIK3CA** mutation. That makes the aspirin-PI3K connection potentially broader here than in tumour types where the pathway story depends more narrowly on mutation status. #### TXA2 and platelet-supported metastasis Gastric cancer also fits aspirin's **anti-metastatic** logic. Higher **TBXA2R** expression has been linked to worse overall survival in pan-cancer analysis that includes gastric tumours. [Read the AACR paper](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf) The newer **TXA2 → ARHGEF1 → CD8+ T-cell suppression** mechanism adds a second reason to pay attention. [Read the Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) That pathway is systemic. It may matter when gastric tumour cells enter the circulation and seed common metastatic sites such as the **liver** or **peritoneum**. For the deeper mechanism page, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). #### Gut and gastric microbial context Another possible layer is microbiota change. Regular aspirin use has been associated with shifts in gut microbial composition that may reduce pro-inflammatory, pro-neoplastic signalling in the gastrointestinal tract. [Read the review](https://www.tandfonline.com/doi/full/10.1080/29937817.2024.2411460) This is still an emerging mechanism. But in a cancer so tied to microbial and inflammatory context, it is worth tracking. ### Clinical positioning | Setting | Evidence | Position | | ------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------ | | **Prevention in *****H. pylori*****-infected patients** | Repeated observational and case-control signal, including up to about **51%** lower risk in a high-incidence population. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) | Strongest current signal | | **Non-cardia, intestinal-type gastric cancer** | Consistent supportive observational pattern across multiple populations. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) | Supportive, but still investigational | | **Cardia or diffuse-type gastric cancer** | Signal is weaker or absent in many studies. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) | Not supported on current evidence | | **After H. pylori eradication** | Biologically plausible and observationally interesting, but no definitive trial. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411598/) | Reasonable research question, not established practice | | **Adjuvant use after surgery or resection** | No Phase 3 gastric-cancer trial exists | Investigational only | | **PIK3CA-mutant gastric cancer** | Genomic and pathway rationale, but no dedicated trial | Biologically plausible, but unproven | ### An important gastric-cancer caution This is one of the hardest cancer types in which to make casual aspirin recommendations. The same organ at risk from the cancer is also the organ at risk from aspirin. That means standard aspirin cautions matter even more here: * prior ulcer or bleed history * altered anatomy after **partial** or **total gastrectomy** * active gastritis or mucosal fragility * anticoagulants, steroids, or other drugs that raise bleeding risk Any real-world aspirin discussion should involve the treating **upper GI**, **oncology**, or **surgical** team. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/40478405/) {% hint style="warning" %} For gastric-cancer patients and survivors, the question is not only "Could aspirin help?" The equally important question is "Is my stomach or post-surgical anatomy in a condition where aspirin is safe enough to discuss at all?" {% endhint %} ### Practical interpretation The gastric-cancer aspirin literature is more encouraging than many people expect. The most convincing part is not a general anti-cancer claim. It is the repeated interaction with ***H. pylori***, **non-cardia location**, and **intestinal-type biology**. For many readers, the most useful questions for the care team are: 1. Was my cancer linked to ***H. pylori***, and has that infection been fully treated? 2. Is my tumour **cardia** or **non-cardia**, and **intestinal** or **diffuse** type? 3. Given my surgery history and current mucosal risk, is **low-dose aspirin** even reasonable to discuss? 4. Has my tumour been tested for **PIK3CA** mutation or other pathway features that make aspirin more biologically interesting? The answer is not automatic. But this is one of the cancer types where the biological rationale is strong enough to justify a careful, well-informed clinical discussion. ### References * 2025 high-incidence population study — regular aspirin use and lower gastric-cancer risk in a high-*H. pylori* setting. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/40478405/) * 2022 review — aspirin and gastric adenocarcinoma, including the ***H. pylori*** interaction. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10022803/) * AACR *Cancer Prevention Research* review — aspirin in gastric-cancer prevention and **COX/*****H. pylori*** biology. [Read the review](https://aacrjournals.org/cancerpreventionresearch/article/15/4/213/682290/Role-of-Aspirin-in-Gastric-Cancer) * 2024 GI-cancers review — aspirin dose effects on the **COX–PGE2** axis. [Read the review](https://www.tandfonline.com/doi/full/10.1080/29937817.2024.2411460) * AACR pan-cancer analysis — **TBXA2R** expression and survival context in gastric cancer. [Read the AACR paper](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf) * Yang et al., *Nature* 2025 — platelet **TXA2**, **ARHGEF1**, and immune suppression in metastasis. [Read the Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) * 2022 review — **PIK3CA**, **COX-2**, and feedback-loop relevance in gastric cancer. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9250486/)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/gastric-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.